NIJMEGEN, Netherlands — ScreenPoint Medical, a pioneer in advanced imaging analysis, has announced a significant leadership change with Pieter Kroese stepping in as the new Chief Executive Officer effective immediately. This transition follows the departure of Mark Koeniguer, who served as CEO since 2022 and played a crucial role in the company’s commercial expansion.
Leadership Transition at ScreenPoint Medical
Pieter Kroese, previously the Chief Operating Officer, will now helm the company, bringing over five years of experience in managing ScreenPoint’s growth from a startup to a leader in the medical imaging field. Under his leadership, ScreenPoint’s flagship product, Transpara, has been integral in supporting millions of scans annually, enhancing breast cancer detection through superior AI-driven technology.
“I am thrilled to lead ScreenPoint into its next phase of growth and innovation,” said Mr. Kroese. “I am deeply committed to building upon the strong foundation we have and continuing to work closely with our talented team to drive continued success. We are already expanding screening capacity and capability through proven reader support – we look forward to increasing our ability to support providers and women moving forward.”
Sir Michael Brady, Chairman of the Board, highlighted Kroese’s deep understanding of the product and market as pivotal for his selection. “Pieter’s remarkable leadership qualities, coupled with his depth of knowledge of our product and industry, make him the perfect choice to lead ScreenPoint into the future. His strategic mindset and commitment to excellence align perfectly with our company mission of early breast cancer detection.”
Dr. Rachel Brem, a Transpara user and ScreenPoint Board Member, also praised Kroese’s capabilities, noting, “Pieter has been an integral part of the ScreenPoint team for years. I am confident that his leadership will continue to deliver product excellence: earlier detection with outstanding reading workflow and improved patient outcomes.”
About ScreenPoint Medical
ScreenPoint Medical is at the forefront of transforming breast cancer detection and screening with its advanced AI-driven platform, Transpara. Developed by leading experts in machine learning and image analysis and continually refined by global feedback, Transpara is recognized worldwide for its precision and effectiveness in enhancing radiologist’s diagnostic capabilities. The company is dedicated to improving patient outcomes through innovative solutions that streamline workflow and increase diagnostic confidence in breast cancer screening.
Also Read : Listening Leaders: The Key to Unlocking Team Potential
